New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC

IASLC shared on X:

“In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven NSCLC. With guests Erin Schenk and Biagio Ricciuti.”

Narjust Florez shared IASLC’s post, adding:

“Amazing discussion about use of Immuno-oncology in patients with Lung Cancer with driver mutations.

Highly recommend this episode, so much learning for these two great guests Drs. Erin Schenk and Biagio Ricciuti.”

Source: IASLC/X and Narjust Florez/X